Abstract
Smartphone applications (“apps”) with artificial intelligence (AI) algorithms are increasingly used in healthcare. Widespread adoption of these apps must be supported by a robust evidence-base and app manufacturers’ claims appropriately regulated. Current CE marking assessment processes inadequately protect the public against the risks created by using smartphone diagnostic apps.
Original language | English |
---|---|
Pages (from-to) | 1749-1750 |
Journal | British Journal of Cancer |
Volume | 124 |
Issue number | 11 |
Early online date | 19 Mar 2021 |
DOIs | |
Publication status | E-pub ahead of print - 19 Mar 2021 |
Bibliographical note
Funding Information:Funding information J.D. is supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (grant reference No BRC-1215-20009). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Cancer Research UK.
ASJC Scopus subject areas
- Oncology
- Cancer Research